Advertisement
UK markets close in 3 hours 21 minutes

  • FTSE 100

    8,042.76
    +18.89 (+0.24%)
     

  • FTSE 250

    19,698.53
    +99.14 (+0.51%)
     

  • AIM

    753.60
    +4.42 (+0.59%)
     

  • GBP/EUR

    1.1620
    +0.0031 (+0.27%)
     

  • GBP/USD

    1.2404
    +0.0054 (+0.44%)
     

  • Bitcoin GBP

    53,340.87
    +216.49 (+0.41%)
     

  • CMC Crypto 200

    1,420.34
    +5.58 (+0.39%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    81.30
    -0.60 (-0.73%)
     

  • GOLD FUTURES

    2,316.00
    -30.40 (-1.30%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,030.49
    +169.69 (+0.95%)
     

  • CAC 40

    8,074.58
    +34.22 (+0.43%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Sanofi Begins Combo Studies on Multiple Myeloma Candidate

Zacks Equity Research
Updated

Sanofi, Inc. SNY announced the start of two new phase III studies evaluating its investigational biologic, isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

While the first study – IKEMA (n=325) – will compare a combination of isatuximab, Amgen’s AMGN Kyprolis (carfilzomib) and dexamethasone to Kyprolis and dexamethasone, the second study IMROZ (n=425) will evaluate a combination of isatuximab, dexamethasone, Celgene’s CELG multiple myeloma drug Revlimid  (lenalidomide) and Japanese firm Takeda’s Velcade (bortezomib) against a combination of Velcade, Revlimid and dexamethasone.

While the IKEMA study will include patients with relapsed/refractory multiple myeloma that have been previously been treated with one-to-three lines of therapy, IMROZ will evaluate the cancer combinations in newly diagnosed multiple myeloma patients not eligible for transplant.

The primary endpoint will be progression-free survival in both the studies

ADVERTISEMENT

Please note that isatuximab is already being evaluated as a monotherapy in phase III studies for relapsed/refractory multiple myeloma and in phase II for acute lymphoblastic leukemia.

Sanofi’s shares have risen 7% so far this year, comparing unfavorably with a gain of 14.7% recorded by the industry.

Sanofi carries a Zacks Rank #4 (Sell).

A better-ranked large-cap pharma stock is Johnson & Johnson JNJ, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Shares of J&J have risen 21.5% this year so far while 2018 earnings estimates have gone up 1.7% in the past 60 days.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Sanofi (SNY) : Free Stock Analysis Report
 
Johnson & Johnson (JNJ) : Free Stock Analysis Report
 
Celgene Corporation (CELG) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research